Collaboration, License and Other Strategic Agreements (Details) - USD ($) $ in Thousands		1 Months Ended			3 Months Ended		12 Months Ended
	Apr. 03, 2017	Feb. 28, 2017	Jul. 31, 2015	Jun. 30, 2013	Sep. 30, 2017	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Collaborative Agreements
Shares issued in connection with Endoceutics License Agreement							$ 13,500
Endoceutics, Inc.
Collaborative Agreements
Payments related to collaborative arrangement	$ 50,000
Number of shares issued under arrangement	600,000
Shares issued in connection with Endoceutics License Agreement	$ 13,500						12,555	$ 0	$ 0
Future contingent payments (up to)							9,300	$ 0	0
Consideration recorded						$ 83,500
IPR&D expense						5,800
Endoceutics, Inc. | 180-day lock-up provision
Collaborative Agreements
Number of shares issued under arrangement	300,000
Stock issued, lock-up period	180 days
Endoceutics, Inc. | One-year lock-up provision
Collaborative Agreements
Number of shares issued under arrangement	300,000
Stock issued, lock-up period	1 year
Palatin Technologies, Inc.
Collaborative Agreements
Payments related to collaborative arrangement		$ 60,000
Out-of-pocket expenses (up to)		$ 25,000
Velo Bio, LLC
Collaborative Agreements
Upfront payment, option agreement									$ 10,000
Velo Bio, LLC | Option Exercise and Regulatory Milestone Achievement
Collaborative Agreements
Future contingent payments (up to)			$ 65,000
Velo Bio, LLC | Annual Sales Milestone Achievements
Collaborative Agreements
Future contingent payments (up to)			250,000
Velo Bio, LLC | Annual Sales Milestone Achievements | Minimum
Collaborative Agreements
Sales milestone targets			100,000
Velo Bio, LLC | Annual Sales Milestone Achievements | Maximum
Collaborative Agreements
Sales milestone targets			$ 900,000
Velo Bio, LLC | Royalty Threshold Achievement
Collaborative Agreements
Potential milestone payment, triggering event, royalty percentage			0.00%
Potential milestone payment, increased percentage			50.00%
Intrarosa | Endoceutics, Inc.
Collaborative Agreements
Out-of-pocket expenses (up to)	$ 20,000
Intrarosa | Endoceutics, Inc. | Developed technology rights
Collaborative Agreements
Finite-lived intangible assets						$ 77,700
Intrarosa | Endoceutics, Inc. | Delivery of Intrarosa Launch Quantities
Collaborative Agreements
Payments related to collaborative arrangement					$ 10,000
Future contingent payments (up to)							10,000
Intrarosa | Endoceutics, Inc. | First Anniversary of Closing
Collaborative Agreements
Future contingent payments (up to)							10,000
Intrarosa | Endoceutics, Inc. | Tiered Royalties
Collaborative Agreements
Potential milestone payment, triggering event, sales	$ 150,000						$ 150,000
Royalty percentage, maximum	20.00%						20.00%
Net sales threshold, future contingent payments	$ 1,000,000						$ 1,000,000
Period after first commercial sale	10 years						10 years
Intrarosa | Endoceutics, Inc. | First Sales Milestone Achievement
Collaborative Agreements
Future contingent payments (up to)	$ 15,000						$ 15,000
Potential milestone payment, triggering event, sales	150,000						150,000
Intrarosa | Endoceutics, Inc. | Second Sales Milestone Achievement
Collaborative Agreements
Future contingent payments (up to)	30,000						30,000
Potential milestone payment, triggering event, sales	300,000						300,000
Intrarosa | Endoceutics, Inc. | Third Sales Milestone Achievement
Collaborative Agreements
Future contingent payments (up to)	850,000						850,000
Potential milestone payment, triggering event, sales	$ 500,000						500,000
Bremelanotide Products | Palatin Technologies, Inc. | Tiered Royalties
Collaborative Agreements
Period after first commercial sale		10 years
Bremelanotide Products | Palatin Technologies, Inc. | First Sales Milestone Achievement
Collaborative Agreements
Future contingent payments (up to)		$ 25,000
Potential milestone payment, triggering event, sales		250,000
Bremelanotide Products | Palatin Technologies, Inc. | Regulatory Milestone Achievement
Collaborative Agreements
Future contingent payments (up to)		80,000					80,000
Bremelanotide Products | Palatin Technologies, Inc. | Regulatory Milestone Achievement, Acceptance by U.S.Food And Drug Administration of New Drug Application
Collaborative Agreements
Future contingent payments (up to)		20,000					20,000
Bremelanotide Products | Palatin Technologies, Inc. | Regulatory Milestone Achievement, U.S.Food and Drug Administration Approval
Collaborative Agreements
Future contingent payments (up to)		60,000					60,000
Bremelanotide Products | Palatin Technologies, Inc. | Achievement of Certain Annual Sales Milestones Over Course of License Agreement
Collaborative Agreements
Future contingent payments (up to)		$ 300,000					$ 300,000
MuGard
Collaborative Agreements
Cost of acquired entity upfront payment				$ 3,300